https://www.invivogen.com/plasmocure

Plasmocure™ - Mycoplasma Elimination Reagent

Alternative mycoplasma removal agent

Plasmocure™ is recommended for the eradication of mycoplasmas that appear, in very rare cases, to be resistant to Plasmocin™.

Plasmocure™ is active against various mycoplasma species that infect mammalian cell cultures including M. hyorhinis, M. orale, M. arginini, M. fermentans, M. hominis and Acholeplasma laidlawii.

Plasmocure™ combines two antibiotics that act through different mechanisms than those found in Plasmocin™.

  • The first antibiotic binds to the 50S subunit of the ribosome and blocks peptidyltransferase activity.
  • The second anticbiotic binds to isoleucyl-tRNA synthetase and halts the incorporation of isoleucine into bacterial proteins.

A two-week treatment with Plasmocure™ is usually sufficient to completely eliminate the mycoplasmas.

A moderate toxicity can be observed during the course of the treatment but full recovery of the cell line is expected once mycoplasmas are eliminated.

Specifications

Product concentration: 100 mg/ml

Elimination of mycoplasmas in two weeks (recommended concentration of 50 μg/ml)

​Endotoxin level: < 0.5 EU/mg

Physicochemical characterization: pH and appearance

Cell culture tested: potency validated on bacterial reference strains

Plasmocure™ para eliminar o micoplasma
Plasmocure™ para eliminar o micoplasma

https://www.invivogen.com/plasmocure

Plasmocure™ - Mycoplasma Elimination Reagent

Alternative mycoplasma removal agent

Plasmocure™ is recommended for the eradication of mycoplasmas that appear, in very rare cases, to be resistant to Plasmocin™.

Plasmocure™ is active against various mycoplasma species that infect mammalian cell cultures including M. hyorhinis, M. orale, M. arginini, M. fermentans, M. hominis and Acholeplasma laidlawii.

Plasmocure™ combines two antibiotics that act through different mechanisms than those found in Plasmocin™.

  • The first antibiotic binds to the 50S subunit of the ribosome and blocks peptidyltransferase activity.
  • The second anticbiotic binds to isoleucyl-tRNA synthetase and halts the incorporation of isoleucine into bacterial proteins.

A two-week treatment with Plasmocure™ is usually sufficient to completely eliminate the mycoplasmas.

A moderate toxicity can be observed during the course of the treatment but full recovery of the cell line is expected once mycoplasmas are eliminated.

Specifications

Product concentration: 100 mg/ml

Elimination of mycoplasmas in two weeks (recommended concentration of 50 μg/ml)

​Endotoxin level: < 0.5 EU/mg

Physicochemical characterization: pH and appearance

Cell culture tested: potency validated on bacterial reference strains